- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in clinical immunotherapy for gastric cancer
Authors
Keywords
Gastric cancer, Immunotherapy, Immune checkpoint inhibitors (ICIs), Biomarkers
Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1876, Issue 2, Pages 188615
Publisher
Elsevier BV
Online
2021-08-15
DOI
10.1016/j.bbcan.2021.188615
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score {greater than or equal to}10
- (2021) Zev A. Wainberg et al. CLINICAL CANCER RESEARCH
- Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
- (2021) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).
- (2021) Yu Sunakawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.
- (2021) Luis Villanueva et al. JOURNAL OF CLINICAL ONCOLOGY
- Sintilimab plus oxaliplatin/capecitabine (CapeOx) as neoadjuvant therapy in patients with locally advanced, resectable gastric (G)/esophagogastric junction (GEJ) adenocarcinoma.
- (2021) Haiping Jiang et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
- (2021) Hope S. Rugo et al. JAMA Oncology
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
- (2021) Narikazu Boku et al. Gastric Cancer
- Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer
- (2021) Ming-jun Zhang et al. INVESTIGATIONAL NEW DRUGS
- Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
- (2021) Jing-Zhou Hou et al. Journal of Hematology & Oncology
- Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.
- (2021) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival.
- (2020) Samuel J. Klempner et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer/testis antigen, Kita-Kyushu lung cancer antigen-1 and ABCD stratification for diagnosing gastric cancers
- (2020) Akiko Shida et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas.
- (2020) S. Derks et al. ANNALS OF ONCOLOGY
- Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer
- (2020) Akinori Sasaki et al. Gastric Cancer
- Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
- (2020) Hiro Sato et al. International Journal of Clinical Oncology
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.
- (2020) Nils Homann et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).
- (2020) Sun Young Rha et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2020) Vincenzo Formica et al. Targeted Oncology
- Development of adoptive immunotherapy with KK‐LC‐1 specific TCR transduced γδ T cells against lung cancer cells
- (2020) Yoshinobu Ichiki et al. CANCER SCIENCE
- Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
- (2020) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial
- (2020) Akihito Kawazoe et al. LANCET ONCOLOGY
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
- (2020) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Cross-species chromatin interactions drive transcriptional rewiring in Epstein–Barr virus–positive gastric adenocarcinoma
- (2020) Atsushi Okabe et al. NATURE GENETICS
- CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer
- (2020) Dominika Bębnowska et al. Journal of Clinical Medicine
- 1445P CS1001, an anti-PD-L1 antibody, combined with standard of care (SOC) chemotherapy for first line (1L) advanced GC/GEJ and ESCC: Preliminary results from 2 phase Ib cohorts of CS1001-101 study
- (2020) L. Shen et al. ANNALS OF ONCOLOGY
- LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study
- (2020) R.J. Kelly et al. ANNALS OF ONCOLOGY
- LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
- (2020) M. Moehler et al. ANNALS OF ONCOLOGY
- Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
- (2020) Haiping Jiang et al. BMC CANCER
- Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
- (2020) Yung-Jue Bang et al. EUROPEAN JOURNAL OF CANCER
- The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
- (2020) Zhi Peng et al. Cancer Immunology Research
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
- (2020) Kohei Shitara et al. JAMA Oncology
- Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
- (2020) Zhihao Lu et al. Journal for ImmunoTherapy of Cancer
- Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy
- (2020) M. Sznol et al. ANNALS OF ONCOLOGY
- Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer
- (2020) Takako Eguchi Nakajima et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
- (2020) Markus Moehler et al. JOURNAL OF CLINICAL ONCOLOGY
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
- (2020) Bairavi Shankar et al. JAMA Oncology
- First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
- (2020) Hyun Cheol Chung et al. Future Oncology
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- FOXP3 and Its Cofactors as Targets of Immunotherapies
- (2019) Yasuhiro Nagai et al. Engineering
- Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
- (2019) Jiang Lv et al. Journal of Hematology & Oncology
- Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study).
- (2019) Hiroki Hara et al. JOURNAL OF CLINICAL ONCOLOGY
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial.
- (2019) Lin Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
- (2019) F Wang et al. ANNALS OF ONCOLOGY
- Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer
- (2019) Megan Greally et al. CLINICAL CANCER RESEARCH
- Immunotherapy for hepatocellular carcinoma: Current and future
- (2019) Michael P Johnston et al. WORLD JOURNAL OF GASTROENTEROLOGY
- L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy
- (2019) H. Angharad Watson et al. Frontiers in Immunology
- Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer
- (2019) Kohei Yamashita et al. Gastric Cancer
- Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1
- (2019) Bridget Marcinkowski et al. Journal for ImmunoTherapy of Cancer
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017
- (2019) Arash Etemadi et al. Lancet Gastroenterology & Hepatology
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- (2018) L Derosa et al. ANNALS OF ONCOLOGY
- Upper gastrointestinal malignancies in 2017: current perspectives and future approaches
- (2018) Benjamin L Solomon et al. Future Oncology
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
- (2018) Koichi Sato et al. LUNG CANCER
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- (2018) Seung Tae Kim et al. NATURE MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment
- (2018) Kelong Tao et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Canonical and Non-Canonical Wnt Signaling in Immune Cells
- (2018) Wook-Jin Chae et al. TRENDS IN IMMUNOLOGY
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Comparison of gastric cancer survival after R0 resection in the US and China
- (2018) Ping Li et al. JOURNAL OF SURGICAL ONCOLOGY
- Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
- (2017) Anshuman Panda et al. JNCI-Journal of the National Cancer Institute
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
- (2017) Yanjing Song et al. Protein & Cell
- Phase II Trial of Adjuvant Immunotherapy with Autologous Tumor-derived Gp96 Vaccination in Patients with Gastric Cancer
- (2017) Kecheng Zhang et al. Journal of Cancer
- Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
- (2017) Anshuman Panda et al. JNCI-Journal of the National Cancer Institute
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
- (2014) P. F. Robbins et al. CLINICAL CANCER RESEARCH
- H. pyloriVirulence Factors: Influence on Immune System and Pathology
- (2014) Behnam Kalali et al. MEDIATORS OF INFLAMMATION
- Totally laparoscopic gastrectomy for gastric cancer: A systematic review and meta-analysis of outcomes compared with open surgery
- (2014) Ke Chen WORLD JOURNAL OF GASTROENTEROLOGY
- Cancer immunotherapy in clinical practice��the past, present, and future
- (2014) Gaurav Goel et al. Chinese Journal of Cancer
- NY-ESO-1 antibody as a novel tumour marker of gastric cancer
- (2013) S Fujiwara et al. BRITISH JOURNAL OF CANCER
- Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer
- (2013) Hajime Ishikawa et al. Gastric Cancer
- Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment
- (2013) Lorin Dodbiba et al. LABORATORY INVESTIGATION
- Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection
- (2010) Y.-Y. Wu et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search